Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.07) by 185.71 percent. This is a 122.22 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $88.00 million which beat the analyst consensus estimate of $80.38 million by 9.48 percent. This is a 20.59 percent increase over sales of $72.97 million the same period last year.